TikoMed

TikoMed is a clinical-stage biotech advancing ILB®, a novel therapeutic with a unique mechanism aimed at modulating disease pathology by stimulating endogenous repair processes. The company is actively progressing its lead program in Amyotrophic Lateral Sclerosis (ALS) into clinical studies and has outlined plans for other indications like myocardial infarction. With a seasoned management team and strategic academic partnerships, TikoMed operates as a privately held, pre-revenue entity following a build-and-exit strategy for its asset portfolio.

ILB®, a novel molecule designed to stimulate the body's own repair mechanisms by modulating disease pathology, potentially reducing triggers for cell death or preventing further progression.

In ALS, TikoMed competes with approved therapies like riluzole and edaravone, and numerous companies developing neuroprotective, anti-inflammatory, and gene therapies. Its differentiation hinges on ILB®'s novel repair-stimulation mechanism. In cardiovascular repair, it would enter a crowded field, competing with standard care and other investigational regenerative approaches.